Report from Annual General Meeting of Vitrolife AB (publ)

At Vitrolife’s Annual General Meeting yesterday, April 28, the following,
amongst other things, was decided:

  · The Board’s proposed dividend of SEK 2.40 per share for the financial year
2015 was approved. Monday May 2, 2016 was adopted as the record day.

  · Re-election of Board members Carsten Browall, Barbro Fridén, Tord Lendau,
Pia Marions, Fredrik Mattsson and Jón Sigurdsson, in accordance with the
election committee’s proposal. Carsten Browall was re-elected Chairman of the
Board.

  · Remuneration to the members of the Board shall be totalling SEK 1,615,000,
of which SEK 500,000 to the Chairman of the Board, SEK 175,000 to each of the
other members of the Board, SEK 60,000 to the Chairman of the Audit
Committee, SEK 60,000 to the Chairman of the Remuneration Committee and SEK
30,000 to the other members of these committees.

  · Authorization for the Board, for the time up until the next Annual General
Meeting and on one or more occasions, to take a decision on the issue of a
maximum of 2,170,000 shares in total, corresponding to just below 10 percent of
the company’s share capital.

  · The Board was authorized to take a decision, up until the next Annual
General Meeting and on one or more occasions, with regard to the acquisition
of the company’s own shares. The Company can at no time hold more than 10
percent of the total shares in the Company.

  · The proposed principles for remuneration and other conditions of employment
for the senior management were approved.

Gothenburg, April 29, 2016
VITROLIFE AB (publ)
The Board
Contact:
Carsten Browall, Chairman of the Board, phone 46 70 255 65 32
Mikael Engblom, CFO, phone 46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on April
29, 2016 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces
and markets medical devices for assisted reproduction. Work is also carried out
to enable the use and handling of stem cells for therapeutic purposes

Vitrolife has approximately 330 employees and the company's products are sold in
almost 110 markets. The company is headquartered in Gothenburg, Sweden, and
there are also offices in USA, Australia, France, Italy, United Kingdom, China,
Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX
Stockholm, Mid Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/